Subcutaneous absorption kinetics of two highly concentrated preparations of recombinant human growth hormone.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are teenagers, adults and middle-aged adults, both men and women.

Participants were recruited from an outpatient clinic and were hospitalized during the two study periods.

Fourteen GH-deficient patients (mean age 25.2 y, range 14-54).

How the Study Was Run

In design terms this was a randomized and crossover study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

Conventional GH therapy was withdrawn 72 hours before each study period.

One patient was excluded from data analysis because of signs of endogenous GH secretion.

The two formulations, PenFill and PenSet, differ in the buffers used and in the relative content of mannitol and glycine.

What Was Measured

PubMed files the paper under topics including Absorption, Biological Availability, Growth Hormone and Recombinant Proteins.

What This Means in Plain Language

The paper is a randomized and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 13 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1993 (The Annals of pharmacotherapy), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.